KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Kalikaki, Aristea ^a   Politaki, Helen ^a   Souglakos, John ^a,b   Apostolaki, Stella ^a   Papadimitraki, Elisavet ^b   Georgoulia, Nefeli ^a   Tzardi, Maria ^b   Mavroudis, Dimitris ^a,b   Georgoulias, Vassilis ^a,b   Voutsina, Alexandra ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAF GENE; CANCER CELL; CANCER TISSUE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CROSS REACTION; DISEASE COURSE; DNA ISOLATION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTATIC COLORECTAL CANCER; MUTANT; ONCOGENE; ONCOGENE K RAS; PIK3CA GENE; POLYMERASE CHAIN REACTION; VERY ELDERLY; WILD TYPE; ADENOCARCINOMA; COLORECTAL NEOPLASMS; GENETICS; HCT116 CELL LINE; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; SECONDARY; TUMOR EMBOLISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; HCT116 CELLS; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASTIC CELLS, CIRCULATING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84929939397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104902     Document Type: Article

References (42)

1. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. (2007) Cetuximab For The Treatment Of Colorectal Cancer. N Engl J Med 357: 2040-2048. (Pubitemid 350106711)
2. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects Of Kras, Braf, Nras, And Pik3ca Mutations On The Efficacy Of Cetuximab Plus Chemotherapy In Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. Lancet Oncol 11: 753-762.
3. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, et al. (2010) Prevalence And Heterogeneity Of Kras, Braf, And Pik3ca Mutations In Primary Colorectal Adenocarcinomas And Their Corresponding Metastases. Clin Cancer Res 16: 790-799.
4. Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, et al. (2012) Primary Colorectal Cancers And Their Subsequent Hepatic Metastases Are Genetically Different: Implications For Selection Of Patients For Targeted Treatment. Clin Cancer Res 18: 688-699.
5. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, et al. (2011) Heterogeneity Of Kras Status May Explain The Subset Of Discordant Kras Status Between Primary And Metastatic Colorectal Cancer. Dis Colon Rectum 54: 1170-1178.
6. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, et al. (2012) Combined Analysis Of Kras And Pik3ca Mutations, Met And Pten Expression In Primary Tumors And Corresponding Metastases In Colorectal Cancer. Mod Pathol 26: 302-313.
7. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, et al. (2012) The Molecular Evolution Of Acquired Resistance To Targeted Egfr Blockade In Colorectal Cancers. Nature 486: 537-540.
8. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence Of Kras Mutations And Acquired Resistance To Anti-Egfr Therapy In Colorectal Cancer. Nature 486: 532-536.
9. Danila DC, Fleisher M, Scher HI (2011) Circulating Tumor Cells As Biomarkers In Prostate Cancer. Clin Cancer Res 17: 3903-3912.
10. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, et al. (2006) Circulating Tumor Cells At Each Follow-Up Time Point During Therapy Of Metastatic Breast Cancer Patients Predict Progression-Free And Overall Survival. Clin Cancer Res 12: 4218-4224.
11. Serrano Fernadez MJ, Alvarez Merino JC, Martinez Zubiaurre I, Fernandez Garcia A, Sanchez Rovira P, et al. (2009) Clinical Relevance Associated To The Analysis Of Circulating Tumour Cells In Patients With Solid Tumours. Clin Transl Oncol 11: 659-668.
12. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation And Prognostic Significance Of Circulating Tumor Cells In Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 29: 1556-1563.
13. Sastre J, Maestro ML, Gomez-Espana A, Rivera F, Valladares M, et al. (2012) Circulating Tumor Cell Count Is A Prognostic Factor In Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group For The Treatment Of Digestive Tumors Study. Oncologist 17: 947-955.
14. Allen JE, El-Deiry WS (2010) Circulating Tumor Cells And Colorectal Cancer. Curr Colorectal Cancer Rep 6: 212-220.
15. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2008) Relationship Of Circulating Tumor Cells To Tumor Response, Progression-Free Survival, And Overall Survival In Patients With Metastatic Colorectal Cancer. J Clin Oncol 26: 3213-3221.
16. Garrigos N, Gallego J, Guillen-Ponce C, Guaraz P, Garcia-Bautista M, et al. (2010) Circulating Tumour Cell Analysis As An Early Marker For Relapse In Stage Ii And Iii Colorectal Cancer Patients: A Pilot Study. Clin Transl Oncol 12: 142-147.
17. Tol J, Koopman M, Miller MC, Tibbe A, Cats A, et al. (2009) Circulating Tumour Cells Early Predict Progression-Free And Overall Survival In Advanced Colorectal Cancer Patients Treated With Chemotherapy And Targeted Agents. Ann Oncol 21: 1006-1012.
18. Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, et al. (2012) Relationship Among Circulating Tumor Cells, Cea And Overall Survival In Patients With Metastatic Colorectal Cancer. Ann Oncol 24: 420-428.
19. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, et al. (2012) Considerations In The Development Of Circulating Tumor Cell Technology For Clinical Use. J Transl Med 10: 138.
20. Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, et al. (2013) Analysing The Mutational Status Of Pik3ca In Circulating Tumor Cells From Metastatic Breast Cancer Patients. Mol Oncol.
21. Di Fiore F, Charbonnier F, Lefebure B, Laurent M, Le Pessot F, et al. (2008) Clinical Interest Of Kras Mutation Detection In Blood For Anti-Egfr Therapies In Metastatic Colorectal Cancer. Br J Cancer 99: 551-552.
22. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, et al. (2012) Heterogeneity Of Epidermal Growth Factor Receptor Status And Mutations Of Kras/Pik3ca In Circulating Tumor Cells Of Patients With Colorectal Cancer. Clin Chem 59: 252-260.
23. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, et al. (2013) Complex Tumor Genomes Inferred From Single Circulating Tumor Cells By Array-Cgh And Next-Generation Sequencing. Cancer Res 73: 2965-2975.
24. Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-De Vries J, et al. (2013) Kras And Braf Mutation Status In Circulating Colorectal Tumor Cells And Their Correlation With Primary And Metastatic Tumor Tissue. Int J Cancer 133: 130-141.
25. Mcshane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting Recommendations For Tumor Marker Prognostic Studies (Remark). Nat Clin Pract Urol 2: 416-422. (Pubitemid 43115010)
26. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, et al. (2012) Combined Analysis Of Kras And Pik3ca Mutations, Met And Pten Expression In Primary Tumors And Corresponding Metastases In Colorectal Cancer. Mod Pathol.
27. Luo JD, Chan EC, Shih CL, Chen TL, Liang Y, et al. (2006) Detection Of Rare Mutant K-Ras Dna In A Single-Tube Reaction Using Peptide Nucleic Acid As Both Pcr Clamp And Sensor Probe. Nucleic Acids Res 34: E12.
28. Sieuwerts AM, Kraan J, Bolt-De Vries J, Van Der Spoel P, Mostert B, et al. (2009) Molecular Characterization Of Circulating Tumor Cells In Large Quantities Of Contaminating Leukocytes By A Multiplex Real-Time Pcr. Breast Cancer Res Treat 118: 455-468.
29. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, et al. (2006) Cell-Free And Cell-Bound Circulating Dna In Breast Tumours: Dna Quantification And Analysis Of Tumour-Related Gene Methylation. Br J Cancer 94: 1492-1495. (Pubitemid 43772286)
30. Coumans FA, Doggen CJ, Attard G, De Bono JS, Terstappen LW (2010) All Circulating Epcam+Ck+Cd45- Objects Predict Overall Survival In Castration-Resistant Prostate Cancer. Ann Oncol 21: 1851-1857.
31. Harb W, Fan A, Tran T, Danila DC, Keys D, et al. (2013) Mutational Analysis Of Circulating Tumor Cells Using A Novel Microfluidic Collection Device And Qpcr Assay. Transl Oncol 6: 528-538.
32. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, et al. (2010) Improving The Yield Of Circulating Tumour Cells Facilitates Molecular Characterisation And Recognition Of Discordant Her2 Amplification In Breast Cancer. Br J Cancer 102: 1495-1502.
33. Ni X, Zhuo M, Su Z, Duan J, Gao Y, et al. (2013) Reproducible Copy Number Variation Patterns Among Single Circulating Tumor Cells Of Lung Cancer Patients. Proc Natl Acad Sci U S A 110: 21083-21088.
34. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, et al. (2014) Tumorigenicity And Genetic Profiling Of Circulating Tumor Cells In Small-Cell Lung Cancer. Nat Med.
35. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, et al. (2012) Isolation And Genomic Analysis Of Circulating Tumor Cells From Castration Resistant Metastatic Prostate Cancer. Bmc Cancer 12: 78.
36. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, et al. (2012) Genomic Profiling Of Isolated Circulating Tumor Cells From Metastatic Breast Cancer Patients. Cancer Res 73: 30-40.
37. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, et al. (2010) Isolation And Characterization Of Circulating Tumor Cells From Patients With Localized And Metastatic Prostate Cancer. Sci Transl Med 2: 25ra23.
38. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection Of Mutations In Egfr In Circulating Lung-Cancer Cells. N Engl J Med 359: 366-377.
39. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME (2010) Detection Of Androgen Receptor Mutations In Circulating Tumor Cells In Castration-Resistant Prostate Cancer. Clin Chem 56: 1492-1495.
40. Stoecklein NH, Klein CA (2009) Genetic Disparity Between Primary Tumours, Disseminated Tumour Cells, And Manifest Metastasis. Int J Cancer 126: 589-598.
41. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, et al. (2008) Circulating Mutant Dna To Assess Tumor Dynamics. Nat Med 14: 985-990.
42. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, et al. (2012) Evaluation Of Circulating Tumor Cells And Circulating Tumor Dna In Non-Small Cell Lung Cancer: Association With Clinical Endpoints In A Phase Ii Clinical Trial Of Pertuzumab And Erlotinib. Clin Cancer Res 18: 2391-2401.